Lupin settles Lunesta patent litigation with Dainippon Sumitomo; Par Pharma starts shipping generic Rythmol and Lotrel
Indian drugmaker Lupin, together with its US subsidiary, Lupin Pharmaceuticals, says it has settled all ongoing litigation over the sedative Lunesta (eszopiclone) tablets, thereby dismissing a patent suit brought by the drug’s manufacturer, Japan’s Dainippon Sumitomo Pharma’s US subsidiary Sunovion Pharmaceuticals.
The settlement entitles Mumbai-based Lupin to sell its generic version of Lunesta under a license as soon as November 30, 2013 (two and a half months prior to the expiry of US Patent 6,444,673). The date would be pushed back to May 31, 2014, if Sunovion obtains six months additional pediatric exclusivity for the product.
US sales of Lunesta were $787 million in the 12 months ended September 2010, according to IMS Health data quoted by the drugmaker.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze